SCHEMBL1279396

SCHEMBL1279396

CC(=O)Oc1ccc(S(=O)(=O)Cl)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.71
POLB P06746 2/20 0.71
PKM P14618 1/20 0.71
LMNA P02545 3/20 0.55
PTGS2 P35354 3/20 0.50
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
KDM4E B2RXH2 2/20 0.49
TTR P02766 1/20 0.49
TP53 P04637 1/20 0.49
CYP3A4 P08684 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ELANE P08246 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HSD17B10 Q99714 1/20 0.47
HSP90AA1 P07900 1/20 0.46
GAA P10253 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
GLA P06280 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4871442 0.86 MAPT (0.52) MAPTPOLBPKMLMNAPTGS2
SCHEMBL1770323 0.84 POLB (0.56) MAPTPOLBPKMLMNAKMT2A
SCHEMBL9343618 0.83 PKM (1.00) MAPTPOLBPKMLMNAPTGS2
SCHEMBL14024262 0.83 MAPT (0.77) MAPTPOLBPKMLMNAPTGS2
SCHEMBL31729674 0.82 ELANE (0.53) MAPTPOLBPKMLMNAPTGS2
SCHEMBL1930857 0.82 MAPT (0.74) MAPTPOLBPKMLMNAPTGS2
SCHEMBL3161812 0.82 MAPT (0.74) MAPTPOLBPKMLMNAPTGS2
SCHEMBL3291980 0.82 PKM (0.47) MAPTPOLBPKMPTGS2KMT2A
SCHEMBL1770600 0.81 POLB (0.53) MAPTPOLBPKMLMNAKMT2A
SCHEMBL65266 0.80 MAPT (0.71) MAPTPOLBPKMLMNAPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777061-A Epoxy functionalized lithium sulfonyl imide and preparation method and application thereof 上海交通大学绍兴新能源与分子工程研究院 2024-03-29 CN claimed
EP-0391652-B1 Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease SQUIBB & SONS INC (US) 1995-03-15 EP claimed
US-20240425450-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. 2024-12-26 US disclosed
WO-2024147287-A1 ACTIVE LIGHT SENSITIVE OR RADIATION SENSITIVE RESIN COMPOSITION, RESIST FILM, PATTERN FORMING METHOD, AND METHOD FOR PRODUCING ELECTRONIC DEVICE 富士フイルム株式会社 2024-07-11 WO disclosed
CN-117777061-A Epoxy functionalized lithium sulfonyl imide and preparation method and application thereof 上海交通大学绍兴新能源与分子工程研究院 2024-03-29 CN disclosed
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. 2023-11-09 US disclosed
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. 2023-11-09 US disclosed
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. 2023-11-09 US disclosed
EP-4210738-A2 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. (US) 2023-07-19 EP disclosed
CN-109153642-B Indole and azaindole halogenated allylamine derivative inhibitors of lysyl oxidase and uses thereof 法玛西斯有限公司 2022-05-17 CN disclosed
WO-2022056369-A2 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS Artizan Biosciences, Inc. (US) 2022-03-17 WO disclosed
EP-0453960-A1 Sulfonylamino substituted bicyclyl hydroxamic acid derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1991-10-30 EP disclosed
US-4916231-A THROMBOXANE A2 RECPTOR ANTAGONISTS SHIONOGI & CO., LTD. (JP) 1990-04-10 US disclosed
US-4904819-A ANTICOAGULANTS, VASODILATORS, BRONCHODILATORS; SALT FORMATION, HYDROLYSIS, ESTERIFICATION SHIONOGI & CO., LTD. (JP) 1990-02-27 US disclosed
EP-0352083-A2 Alkenyltetrazole derivatives, their preparation and use SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1990-01-24 EP disclosed
EP-0199672-B1 OXIME SULPHONATES CONTAINING REACTIVE GROUPS CIBA-GEIGY AG (CH) 1988-06-01 EP disclosed
US-4736055-A STARING MATERIAL FOR PHOTORESIST POLYMERS CIBA-GEIGY CORPORATION (US) 1988-04-05 US disclosed
EP-0199672-A1 Oxime sulphonates containing reactive groups CIBA-GEIGY AG (CH) 1986-10-29 EP disclosed
US-4443536-A CONTAINING BALLAST WITH HYDROXYPHENYLSULFINYL OR HYDROXYPHENYLSULFONYL GROUP EASTMAN KODAK COMPANY (US) 1984-04-17 US disclosed
EP-0073636-A1 Photographic elements containing ballasted couplers EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1983-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357139-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS FABP2, APC, SI MAPT 4222/4885POLB 604/4885PKM 3645/4885
US-20240425450-A1 SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS FABP2, APC, SI MAPT 4222/4885POLB 604/4885PKM 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.